AD/PD 2023 and Treatment View overview page

Transcranial pulse stimulation for the treatment of Alzheimer’s disease

Boosting neurogenesis with NA-831: Phase III trial update

How does TPS work in Alzheimer’s disease?

Boosting lysosomal function in microglia to treat Alzheimer’s disease

Novel genome editing approaches under investigation in Alzheimer’s disease

Anti-amyloid combination strategies in Alzheimer’s disease

Next-generation anti-amyloid therapies: prioritizing selectivity

Sex differences in Alzheimer’s disease: women’s journey, challenges, and implications

Why have anti-amyloid monoclonal antibodies performed differently in Phase III trials

TRAILBLAZER-ALZ 4: direct comparison of donanemab and aducanumab

Safety results of the Phase III gantenerumab GRADUATE I and II studies

Improving the next generation of anti-amyloid antibodies: prioritizing selectivity with PMN310

Symptomatic versus disease modifying treatments

Defining subgroups of patients with subjective cognitive decline more likely to progress

European task force recommendations: shifting memory clinics towards prevention

Distinguishing between disease modifying and symptomatic effects in clinical trials